Annual Review of Cancer Biology

Scope & Guideline

Charting New Directions in Cancer Studies

Introduction

Delve into the academic richness of Annual Review of Cancer Biology with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN2472-3428
PublisherANNUAL REVIEWS
Support Open AccessNo
CountryUnited States
TypeBook Series
Convergefrom 2017 to 2020, from 2022 to 2024
AbbreviationANNU REV CANCER BIOL / Ann. Rev. Cancer Biol.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139

Aims and Scopes

The Annual Review of Cancer Biology aims to provide a comprehensive overview of significant advancements in cancer research, focusing on molecular and cellular mechanisms, therapeutic developments, and innovative methodologies. The journal serves as a platform for scholars to disseminate insights that can enhance our understanding of cancer biology and improve treatment strategies.
  1. Molecular Mechanisms of Cancer:
    The journal emphasizes the exploration of molecular pathways and genetic alterations that drive cancer development and progression. This includes studies on oncogenes, tumor suppressor genes, and signaling pathways.
  2. Innovative Therapeutics and Treatment Strategies:
    A core focus is on the discovery and evaluation of novel therapeutic approaches, including targeted therapies, immunotherapies, and combination treatments that enhance efficacy against various cancer types.
  3. Cancer Microenvironment and Metabolism:
    Research on the interplay between cancer cells and their surrounding microenvironment, as well as metabolic reprogramming in tumors, is a significant area of interest, highlighting how these factors influence tumor behavior and therapeutic responses.
  4. Genomic and Epigenomic Profiling:
    The journal covers advancements in genomic and epigenomic profiling techniques that provide insights into the heterogeneity of tumors and can inform personalized medicine approaches.
  5. Clinical Applications and Translational Research:
    There is a strong emphasis on translating laboratory findings into clinical applications, including the development of biomarkers for diagnosis and prognosis, as well as strategies for improving patient outcomes.
The Annual Review of Cancer Biology reflects emerging trends in cancer research, showcasing the journal's responsiveness to new scientific discoveries and innovations. Recent publications highlight several themes that are gaining traction.
  1. Immunotherapy and Immune Modulation:
    There is a notable increase in research related to immunotherapy, including CAR T-cell therapies and checkpoint inhibitors, reflecting a growing interest in harnessing the immune system to combat cancer.
  2. Epigenetics and Cancer:
    The exploration of epigenetic mechanisms and their role in cancer biology is on the rise, with studies focusing on histone modifications and the implications for therapy, indicating a deeper understanding of gene regulation in cancer.
  3. Metabolic Reprogramming:
    Recent papers emphasize the role of altered metabolism in cancer progression and therapy resistance, highlighting the importance of understanding metabolic pathways as potential therapeutic targets.
  4. Digital Pathology and Computational Approaches:
    The application of digital pathology, AI, and machine learning in cancer diagnosis and treatment is increasingly relevant, showcasing the integration of technology in cancer research.
  5. Microbiome and Cancer Interactions:
    Emerging research is focusing on the relationship between the microbiome and cancer, particularly how gut microbiota can influence therapeutic responses, which opens new avenues for personalized treatment strategies.

Declining or Waning

While the Annual Review of Cancer Biology continues to evolve, certain themes have shown a decline in frequency or interest over recent years. This may reflect shifting research focuses or advancements in other areas of cancer biology.
  1. Traditional Chemotherapy Approaches:
    There appears to be a waning interest in discussing traditional chemotherapy alone, as the field increasingly emphasizes targeted and personalized therapies that aim to mitigate the limitations of conventional treatments.
  2. Single-Agent Therapies:
    The publication of papers focusing solely on single-agent therapeutic strategies has decreased, indicating a shift towards exploring combination therapies that enhance efficacy and reduce resistance.
  3. Basic Research on Established Cancer Types:
    There is a decline in focus on well-established cancer types like breast and prostate cancer in favor of emerging areas such as rare cancers or those with unique biological characteristics.
  4. Non-targeted Radiation Therapies:
    Research focused on conventional radiation therapy techniques is diminishing, as novel approaches like FLASH radiotherapy and combination strategies with immunotherapy gain prominence.

Similar Journals

NEOPLASIA

Leading the way in transformative oncology discoveries.
Publisher: ELSEVIER SCIENCE INCISSN: 1476-5586Frequency: 12 issues/year

NEOPLASIA is an esteemed open-access journal dedicated to advancing the field of oncology, published by Elsevier Science Inc. since 1999. With an impressive impact factor and recognition as a Q1 journal in Cancer Research for 2023, it holds a significant position within the scientific community, specifically ranking in the 74th percentile globally in the categories of Biochemistry, Genetics, and Molecular Biology. NEOPLASIA seeks to provide a comprehensive platform for innovative research, covering a wide array of topics in cancer biology, treatment methodologies, and therapeutic advancements. Researchers, professionals, and students are encouraged to utilize this resource, which is easily accessible to foster collaboration and stimulate progress in cancer research. As it converges its efforts towards the future of oncology, this journal is poised to remain at the forefront of transformative discoveries that shape our understanding and treatment of cancer.

Journal of Cancer

Bridging knowledge gaps in cancer studies.
Publisher: IVYSPRING INT PUBLISSN: 1837-9664Frequency: 12 issues/year

Journal of Cancer is a premier, peer-reviewed academic journal published by IVYSPRING INTERNATIONAL PUBLISHING that focuses on advancing the field of oncology. With an impact factor reflecting its significant contributions, this journal ranks in the 80th percentile of medical journals pertaining to oncology, positioning it at #79 out of 404 in Scopus. Since its inception in 2010, the journal has embraced an Open Access model, ensuring that groundbreaking research reaches a global audience without barriers. Based in Australia, the journal addresses a wide array of topics within cancer research, catering to researchers, healthcare professionals, and students committed to enhancing their understanding of the complexities of cancer. Amidst evolving challenges in oncology, the Journal of Cancer serves as a vital platform for disseminating innovative findings, fostering collaboration, and promoting informed decisions that can lead to improved cancer outcomes worldwide.

NEOPLASMA

Illuminating the Pathways of Oncology
Publisher: AEPRESS SROISSN: 0028-2685Frequency: 6 issues/year

NEOPLASMA is a prominent journal published by AEPRESS SRO, dedicated to the multifaceted field of oncology and cancer research. Since its inception in 1957, this esteemed publication has served as a vital platform for advancing the understanding of neoplastic diseases, disseminating high-quality research findings that contribute to clinical and laboratory advancements. Operating under a robust framework of peer review, NEOPLASMA holds significant credibility, as evidenced by its Q2 ranking in the Medicine (miscellaneous) category and Q3 rankings in both Cancer Research and Oncology for 2023. Furthermore, with an ISSN of 0028-2685 and E-ISSN 1338-4317, the journal fosters accessibility to valuable scientific content despite the absence of open access options. Positioned in Bratislava, Slovakia, NEOPLASMA continues to attract a global readership, making substantial contributions to the fields of biochemistry, genetics, and molecular biology as highlighted by its Scopus rankings. This journal is essential reading for researchers, professionals, and students looking to stay abreast of the latest developments in cancer research and treatment strategies.

INTERNATIONAL JOURNAL OF ONCOLOGY

Transforming discoveries into impactful cancer solutions.
Publisher: SPANDIDOS PUBL LTDISSN: 1019-6439Frequency: 12 issues/year

INTERNATIONAL JOURNAL OF ONCOLOGY is a leading academic publication dedicated to advancing the field of cancer research and treatment. Published by SPANDIDOS PUBL LTD in Greece, this journal, with ISSN 1019-6439 and E-ISSN 1791-2423, has established itself as a reputable source of peer-reviewed articles since its inception in 1993. With an impressive Q2 ranking in both Cancer Research and Oncology categories, as well as high Scopus ranks reflecting its significant contribution to the fields of Medicine and Biochemistry, the journal offers a platform for researchers, clinicians, and students alike to disseminate their findings and engage in dialogue surrounding innovative practices and breakthroughs. Although the journal follows a traditional subscription model, it continues to attract a diverse readership interested in the latest developments in oncological research, providing essential insights into cancer biology, therapeutics, and patient care. With a commitment to excellence, the INTERNATIONAL JOURNAL OF ONCOLOGY plays a vital role in shaping the future of oncology research and is a must-read for anyone passionate about advancing cancer treatment and prevention.

MOLECULAR CARCINOGENESIS

Exploring the Frontiers of Cancer Research
Publisher: WILEYISSN: 0899-1987Frequency: 12 issues/year

MOLECULAR CARCINOGENESIS is a prestigious academic journal published by Wiley, dedicated to advancing the understanding of the molecular basis of cancer. Established in 1988, this journal serves as a vital resource for researchers and professionals in the fields of cancer research and molecular biology. With an impressive impact factor reflecting its significance in the Q2 category for both Cancer Research and Molecular Biology, it stands out for its high-quality, peer-reviewed articles that explore innovative research, novel findings, and emerging trends in carcinogenesis. Although the journal currently does not offer open access options, it remains accessible to the academic community through numerous institutional subscriptions. Positioned in the United States and contributing to the global discourse on cancer research, MOLECULAR CARCINOGENESIS is an essential publication for anyone engaged in the study of cancer at the molecular level.

JCO Precision Oncology

Elevating Treatment Strategies Through Genetic Insights
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: Frequency: 1 issue/year

JCO Precision Oncology, published by Lippincott Williams & Wilkins, is a leading journal in the field of cancer research and oncology, recognized for its high-impact contributions and innovative approaches to precision medicine. Since its inception in 2017, this journal has consistently ranked in the Q1 category in both Cancer Research and Oncology for 2023, reflecting its esteemed position within the academic community. With a rigorous peer-review process and a focus on disseminating cutting-edge research, JCO Precision Oncology serves as a vital platform for researchers, clinicians, and healthcare professionals aiming to enhance the understanding and treatment of cancer through individualized therapies. The journal's comprehensive scope includes studies on genetic profiling, biomarker research, and novel therapeutic strategies, making it an essential resource for anyone involved in cancer care and research. Explore further and join a community committed to advancing precision oncology and improving patient outcomes.

Journal of Cancer Metastasis and Treatment

Transforming cancer care with cutting-edge studies.
Publisher: OAE PUBLISHING INCISSN: 2394-4722Frequency: 1 issue/year

Journal of Cancer Metastasis and Treatment, published by OAE PUBLISHING INC, stands as a vital resource in the field of oncology, focusing on advancements and research pertaining to cancer metastasis and treatment methodologies. With an ISSN of 2394-4722 and an E-ISSN of 2454-2857, this journal aims to serve as a comprehensive platform for sharing innovative research, critical analyses, and novel findings from 2019 through 2024. As indexed in Scopus, it holds a notable Q3 ranking within its category, positioned at 240/404 and within the 40th percentile, thus reflecting its growing significance in the scientific community. Though currently not open access, the journal aspires to improve accessibility to pivotal oncology research, making it an essential tool for researchers, clinicians, and students keen on unraveling the complexities of cancer treatment and metastasis. Its commitment to promoting high-quality studies plays a crucial role in the ongoing quest to enhance patient care and outcomes in cancer treatment.

GENES CHROMOSOMES & CANCER

Bridging Genetics and Cancer for a Healthier Tomorrow.
Publisher: WILEYISSN: 1045-2257Frequency: 12 issues/year

GENES CHROMOSOMES & CANCER, published by Wiley, is a premier journal in the intertwined fields of cancer research and genetics. With an ISSN of 1045-2257 and an e-ISSN of 1098-2264, this journal has been a significant outlet for innovative research since its inception in 1989, continuing through to 2024. Positioned in the Q2 quartile of both Cancer Research and Genetics categories in 2023, it reflects a strong impact in the scientific community, as evidenced by its Scopus rankings—99th in Genetics and 83rd in Cancer Research. Though it does not provide open access options, GENES CHROMOSOMES & CANCER offers valuable insights that foster collaboration and discovery among researchers, professionals, and students dedicated to understanding the genetic underpinnings of cancer. With its reputable standing, this journal is a vital resource for those aspiring to contribute meaningful advancements in cancer genetics and therapeutic interventions.

CANCER INVESTIGATION

Exploring the frontiers of cancer research with precision.
Publisher: TAYLOR & FRANCIS INCISSN: 0735-7907Frequency: 10 issues/year

CANCER INVESTIGATION is a distinguished peer-reviewed journal published by Taylor & Francis Inc, dedicated to the advancing field of cancer research and oncology. With an ISSN of 0735-7907 and E-ISSN of 1532-4192, this journal has been a pivotal resource for professionals and researchers since its inception in 1983, continually contributing to the evolving landscape of cancer investigation until its convergence in 2024. CANCER INVESTIGATION boasts noteworthy rankings in 2023, including Q3 in Cancer Research and Q2 in Medicine (miscellaneous), highlighting its relevance and impact in these critical areas. The journal's commitment to disseminating innovative research and comprehensive reviews makes it an essential platform for those engaged in cancer studies and related disciplines. While currently not available as an open-access publication, CANCER INVESTIGATION remains an invaluable tool for understanding the complexities of cancer, offering insights that drive scientific advancements and improve patient outcomes.

INTERNATIONAL JOURNAL OF CANCER

Shaping the future of oncology through rigorous research.
Publisher: WILEYISSN: 0020-7136Frequency: 24 issues/year

INTERNATIONAL JOURNAL OF CANCER, published by Wiley, stands as a premier platform for the dissemination of cutting-edge research in the fields of cancer research and oncology. With an impressive impact factor reflecting its rigorous peer-review process and significant contribution to the scientific community, this journal is categorized in Q1 for both Cancer Research and Oncology as of 2023. It boasts notable rankings, being placed 38th among 404 journals in Medicine - Oncology and 32nd among 230 in Biochemistry, Genetics, and Molecular Biology - Cancer Research, positioning it within the 90th and 86th percentiles, respectively. Since its inception in 1966 and continuing to 2024, the journal has played a pivotal role in advancing our understanding of cancer biology, treatment modalities, and innovative therapeutic approaches. While it operates under a subscription model, the journal is committed to making valuable research accessible to a broader scientific audience. Researchers, professionals, and students alike will find the INTERNATIONAL JOURNAL OF CANCER an essential resource for staying abreast of the latest advancements in cancer science.